Belardinelli Luiz, Antzelevitch Charles, Vos Marc A
CV Therapeutics, 3172 Porter Drive, Palo Alto, CA 94304, USA.
Trends Pharmacol Sci. 2003 Dec;24(12):619-25. doi: 10.1016/j.tips.2003.10.002.
Torsades de pointes (TdP) is a malignant polymorphic ventricular tachyarrhythmia that can be caused by drugs that induce electrophysiological changes. Although the number of drugs known to cause TdP has increased in recent years, there is no cell-based assay, in vitro heart preparation or animal model that predicts the potential of a drug to induce TdP in humans. Nevertheless, certain electrophysiological events are known to be associated with the development of TdP. For example, a drug that prolongs action potential duration, induces early afterdepolarizations and ectopic beats, and increases dispersion of ventricular repolarization is likely to cause TdP. By contrast, a drug that does not induce these changes is unlikely to cause TdP. The exact relationship between these electrophysiological events and the development of TdP has not been defined, but the potential of a drug to elicit these events might predict its pro-arrhythmic risk.
尖端扭转型室性心动过速(TdP)是一种恶性多形性室性快速心律失常,可由诱导电生理变化的药物引起。尽管近年来已知可导致TdP的药物数量有所增加,但尚无基于细胞的检测方法、体外心脏制剂或动物模型能够预测药物在人类中诱发TdP的可能性。然而,某些电生理事件已知与TdP的发生有关。例如,一种延长动作电位时程、诱发早期后除极和异位搏动并增加心室复极离散度的药物很可能导致TdP。相比之下,一种不诱发这些变化的药物不太可能导致TdP。这些电生理事件与TdP发生的确切关系尚未明确,但药物引发这些事件的可能性可能预示其促心律失常风险。